ABL Bio Inc (298380) — Cash Flow-to-Debt Ratio
ABL Bio Inc (298380) has a Cash Flow-to-Debt Ratio of -0.23x as of June 2026, meaning its operating cash flow of ₩-23.42 Billion could theoretically repay 0% of its total liabilities (₩99.78 Billion) in one year. See ABL Bio Inc (298380) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ABL Bio Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for ABL Bio Inc across 10 annual periods. For the full cash flow conversion analysis, see ABL Bio Inc (298380) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for ABL Bio Inc (2016–2025)
Year-by-year debt coverage analysis for ABL Bio Inc. Check 298380 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.33x | ₩-41.25 Billion | ₩124.24 Billion | ▲ +69.0% |
| 2024 | -1.07x | ₩-69.40 Billion | ₩64.70 Billion | ▼ -225.5% |
| 2023 | -0.33x | ₩-28.36 Billion | ₩86.07 Billion | ▼ -152.8% |
| 2022 | 0.62x | ₩72.13 Billion | ₩115.67 Billion | ▲ +114.6% |
| 2021 | -4.27x | ₩-40.61 Billion | ₩9.50 Billion | ▲ +16.6% |
| 2020 | -5.12x | ₩-47.29 Billion | ₩9.23 Billion | ▼ -134.0% |
| 2019 | -2.19x | ₩-23.86 Billion | ₩10.89 Billion | ▼ -105.8% |
| 2018 | -1.06x | ₩-12.67 Billion | ₩11.91 Billion | ▼ -1483.8% |
| 2017 | -0.07x | ₩-7.14 Billion | ₩106.32 Billion | ▲ +57.7% |
| 2016 | -0.16x | ₩-3.12 Billion | ₩19.63 Billion | — |